News

Open call for SMEs and start-ups: experiments with supercomputers and scaling up generative AI applications

Published on
| 2 years ago
Programmes
  • Digital, Industry & Space
  • HPC
  • AI Continent

The FFPlus project has opened the first out of six round of open calls to set up experiments with supercomputers and to scale up generative AI applications. 

FFplus is a European initiative highlighting and promoting the adoption of High-Performance Computing (HPC) by SMEs and start-ups across Europe, showing the business benefits and impacts of adopting HPC and AI in real business models. 

There are two types of open calls:

Business experiments: 

  • Max. funding budget: 200.000€
  • Target group: SMEs new to HPC
  • Aim: address specific business challenges using HPC
  • Duration: up to 15 months, starting January 2025 for this first round of open calls
  • Funding: part of a 4 million€ total budget

Innovation studies:

  • Max. funding budget: 200.000€ for the main participant
  • Target group: SMEs and start-ups active in generative AI
  • Aim: assist in scaling up operations that require extensive computational resources
  • Duration: up to 10 months, starting December 2024 for this first round of open calls
  • Funding: part of a 4 million€ total budget

More information can be found on the FFPlus website, for questions you can also contact the Flemish Supercomputer Center (VSC) via this link.

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2055 articles available Browse all news
  • Health

One Health AMR Partnership: Call 2027 opening soon

The European Partnership on One Health Antimicrobial Resistance (OH AMR) is about to launch the joint transnational call 2027 (JTC2027) “Understand, Model and Stop AMR Transmission”. The call opens on 18 November 2026. The call will follow a two-step evaluation process.Novel and improved measures are urgently required...

Read more
  • Enhancing EU R&I

ERA in Practice: A guide for the research and innovation community

The European Commission Directorate-General for Research & Innovation has published ERA in Practice: A Guide for the R&I Community, developed with the support of INSPIRING ERA. The publication connects the four European Research Area policy priorities for joint action of the Pact for Research and Innovation (2021), with practical tools...

Read more
  • Culture and society

SSH Opportunities document for the 2027 Horizon Europe calls updated

Net4Society, the NCP network for Cluster 2, has published an updated edition of the document "Opportunities for Researchers from the Social Sciences and Humanities (SSH) in Horizon Europe". This document is designed to help potential applicants to find SSH-related call topics across the different parts of Horizon Europe in Work Programmes...

Read more
  • Agro-Food, Environment

Topic update - HORIZON-CL6-2027-02-FARM2FORK-05

On 5 November 2026, the European Commission published a correction for Horizon Europe topic HORIZON-CL6-2027-02-FARM2FORK-05. Under the section ‘Topic description - Scope’, the sentence on collaboration with projects funded under other topics in the work programme has been updated. The original text referred to...

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.